About Us

Our history, our mission and our values tell the story of who we are as a company. We began as a pharmaceutical distributor, providing products to customers in smaller communities.

Today we’re one of the world’s leading generics and specialty pharmaceutical companies, with products in approximately 140 countries and territories. And our dedication to providing access to medicine continues to grow after more than 50 years.

  1. History
    0
    History

    1961: Day 1

    First known as Milan, the company starts doing business in White Sulphur Springs, West Virginia. U.S. Army chums, Milan "Mike" Puskar and Don Panoz flip a coin to see who will name the business and who will be the company’s first president. They start distributing products to doctors and chemists from an old Pontiac Bonneville.

    History
  2. 0
    Mylan FDA approval

    1965: Moves to Morgantown

    We move to Morgantown, West Virginia in 1965 and begin manufacturing various over-the-counter products the next year. Success leads to a decision to switch production to generic pharmaceuticals.

    Mylan FDA approval
  3. Mylan FDA approval
    0
    Mylan Penicillin G

    1966: Our First Medicine

    After receiving approval from the FDA to manufacture our first medicine, Penicillin G, we broaden our product line to include other generic antibiotics as well as analgesics, antihistamines, diuretics and tranquillisers. We market these to large drug companies, chemist chains and mail-order drug providers, all for resale under the customers’ own labels.

    Mylan Penicillin G
  4. 1969: New Partner, New Look
    0

    1969: New Partner, New Look

    Parke-Davis is the first major pharmaceutical company to purchase and privately label Milan products. We also introduce a new logo—the letter “M” formed by three test tubes suggests scientific leadership and teamwork.

  5. 1972: From Milan to Mylan
    0

    1972: From Milan to Mylan

    We change the spelling of Mylan to stand out at the bottom of the list of stocks that begin with the letter "M."

  6. Mylan goes public
    0
    1973: Mylan Going Public

    1973: Going Public

    To fuel expansion, Mylan goes public. By the end of the 1970s, we produce five of the 10 most prescribed generic medicines—all five are antibiotics.

    1973: Mylan Going Public
  7. 0
    1976: New Leadership

    1976: New Leadership

    Mike Puskar, who had left the company, returns as president. He and chairman and CEO Roy McKnight lead Mylan through a period of unprecedented growth.

    1976: New Leadership
  8. Generic Pharmaceutical Industry Association
    0
    1982: GPIA and Hatch-Waxman

    1982: GPIA and Hatch-Waxman

    Mike Puskar helps establish the Generic Pharmaceutical Industry Association, GPIA, to give the industry a voice. During the next few years, GPIA lobbies for the Hatch-Waxman Act, which is passed in 1984.

    1982: GPIA and Hatch-Waxman
  9. First-to-Market
    0
    1984: First to Market

    1984: First to Market

    Our first branded product approval, for MAXZIDE® TABLETS (triamterene and hydrocholorothiazide tablets, US), is a first for a generics company.

    1984: First to Market
  10. 0
    1986: Doing What’s Right, Not What’s Easy

    1986: Doing What’s Right, Not What’s Easy

    We see irregularities in how the Food and Drug Administration (FDA) acts on ANDAs, abbreviated new drug applications. Our investigation helps expose fraudulent practices and corruption in the industry. This results in reform of the FDA’s review procedures for generic drugs and new precautions to help ensure consumer safety.

    1986: Doing What’s Right, Not What’s Easy
  11. Bertek & UDL Labs
    0

    1993-1996: Diversification

    The market is becoming increasingly competitive as demand for high-quality, affordable medication rises.

    • In 1993, we acquire Bertek Inc., an innovator of transdermal medicine systems. Bertek is later renamed Mylan Technologies Inc., or MTI
    • In 1996, Mylan adds unit dose packaging with the acquisition of UDL, the largest pharmaceutical unit dose packaging company in the United States
    • At the same time, generic use rises to about 47%, and we continue to capture market share while discontinuing private labelling and growing our own “Mylan” label

  12. 0
    1993: New CEO

    1993: New CEO

    Mike Puskar becomes chairman and CEO.

    1993: New CEO
  13. Biggest pharma companies
    0
    1995: Another First

    1995: Another First

    We become the most-dispensed line of brand and generic pharmaceuticals in the U.S.

    1995: Another First
  14. Mylan 2002 revenue
    0
    Mylan packaging

    2002: Growing Into the 21st century

    Soon after entering our fifth decade, we declare a turnover of $1 billion.

    Mylan packaging
  15. 0
    Robert J. Coury

    2002: Robert J. Coury

    Robert J. Coury is elected to the board of directors and becomes vice chairman and CEO.

    Robert J. Coury
  16. 0
    2004: Added to S&P 500

    2004: Added to S&P 500

    In 2004, Mylan was added to the S&P 500 and shipped eleven billion doses, more than any other pharmaceutical company.

    2004: Added to S&P 500
  17. Generic vs. Brand
    0
    2004-2006: Organic Growth

    2004-2006: Organic Growth

    In the U.S., the Medicare Prescription Drug, Improvement and Modernization Act and an ageing Medicare population fuel generic use, which reaches 78% by the end of the decade. We are ready, having put in place a plan to expand through organic growth and acquisitions from a mid-size company into a global leader.

    2004-2006: Organic Growth
  18. 0
    2006: Setting New standards in health care

    2006: Setting New Standards in Health Care

    Executive Heather Bresch testifies before the U.S. Senate’s Special Committee on Ageing regarding issues that put billions of dollars of consumer healthcare savings at risk.

    2006: Setting New standards in health care
  19. Mylan Global
    0
    Matrix Labs

    2007: Going Global

    We become a global company by acquiring a controlling interest in Matrix Laboratories, a supplier of active pharmaceutical ingredients (API), and by purchasing Merck KGaA’s generics business.

    • Matrix has low-cost manufacturing facilities in India and China and marketing capabilities in Western Europe and Africa. Matrix gives us unprecedented control over our supply chain and expands our dosage forms and therapeutic categories. This includes the addition of antiretroviral medicines for people living with HIV/AIDS
    • Merck KGaA’s generic business sells products in more than 90 countries. Combining forces provides massive global scale, expands our product portfolio and provides entry into new commercial markets
    • With the acquisition of Merck KGaA generic business, we acquire the rights to EpiPen®(adrenaline) Auto-Injector, the world's No. 1 dispensed adrenaline auto-injector*
    • *IMS data, 1987-2012
    Matrix Labs
  20. Mylan 2008 revenue
    0
    2008: Continued Growth

    2008: Continued Growth

    We declare a turnover of $5 billion.

    2008: Continued Growth
  21. 2009
    0
    2009: Global Leadership

    2009: Global Leadership


    • Mike Puskar retires and Robert J. Coury is named chairman of the board.
    • We launch next-generation EpiPen® Auto-Injector (adrenaline).
    • Our first global product, LANSOPRAZOLE (lansoprazole capsule, delayed release pellets), launches.
    • Lopinavir/Ritonavir, an innovative heat-stable ARV treatment, is created for use in certain countries where refrigeration isn't readily available.
    • Robert J. Coury and former President Bill Clinton announce an agreement for better, more affordable treatment for HIV/AIDS patients in the developing world.
    *Mylan is appointed to the Fortune 500 list.
    2009: Global Leadership
  22. 0
    2010: Bioniche Pharma

    2010: Bioniche Pharma

    Our acquisition of Bioniche Pharma expands our injectable portfolio with products for use in orthopaedics, rheumatology, urology and dermatology.

    2010: Bioniche Pharma
  23. 0
    Mylan book

    2011: Our First 50 Years

    • Mylan celebrates 50 years of unconventional success.
    • We acquire Pfizer’s respiratory delivery platform.
    Mylan book
  24. FDASIA
    0
    GDUFA

    2012: Championing National Policy

    Mylan, led by Heather Bresch, champions the Food and Drug Administration Safety and Innovation Act (FDASIA), which holds both foreign and domestic manufacturers to one global quality standard. The Act includes the Generic Drug User Fee Act (GDUFA). Together, FDASIA and GDUFA aim to speed up access to safe and effective generic medicines while providing more visibility into how medicines and their ingredients are manufactured and shipped around the world.

    Read more >

    GDUFA
  25. 0
    Mylan Executives

    2012: Expanding Leadership

    We introduce a new and expanded management structure to help fuel our continued growth and success. Robert J. Coury transitions into the role of executive chairman of the board. Heather Bresch is promoted to CEO; Rajiv Malik is promoted to president.

    Mylan Executives
  26. 0
    Mylan India

    2012: Unprecedented Growth

    • We launch commercial operations in India and team up with Pfizer in Japan
    • Mylan is selected as a supplier to India’s National AIDS Control Organization and is named the leading antiretroviral supplier to the South African National Department of Health
    • Nearly 40% of patients receiving treatment in developing countries are using a Mylan product
    Mylan India
  27. 0
    Mylan Headquarters

    2013: New Global Centre

    Operations begin at our new Robert J. Coury Global Centre in Pittsburgh, Pennsylvania, a 280,000-square-foot, five-story innovative workspace.

    Mylan Headquarters
  28. 0
    Agila

    2013: Ongoing Global Leadership

    • Our antiretroviral portfolio launches in South Africa
    • EpiPen®(adrenaline) Auto-Injector celebrates 25 years as the No. 1 prescribed adrenaline auto-injector in the U.S.*
    • Mylan acquires Agila Specialties creating a global injectables leader
    • *IMS data, 1987-2012
    Agila

Mylan’s Mission

At Mylan, we are committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we:

  • Innovate to satisfy unmet needs
  • Make reliability and service excellence a habit
  • Do what’s right, not what’s easy
  • Impact the future through passionate global leadership

Our Values

Innovation
We are unconventional, visionary and bold. We “connect the dots” others overlook. We see possibilities and bring them to life. We love to challenge the status quo and introduce new and better ways to help people everywhere enjoy a higher quality of life. Having the courage to be a force for constructive change is in our DNA.

We see the opportunity to innovate in every challenge

Integrity
Doing what's right is sacred to us. We behave responsibly, even when nobody's looking. We set high standards from which we never back down. This uncompromising ethical stance helps to keep our products pure, our workers safe and the environment clean.

Watch our Integrity at work

Reliability
Dependable. Reliable. Call it what you will, we've made it a habit. We strive to be there through thick and thin, rain or shine, delivering on every promise, every time. That's why people around the corner and across the world count on Mylan.

Seven billion people rely on us

Service
We understand that "it's not about us"—it's about helping others—and we believe there's no situation we can't handle. We would do whatever it takes, work ‘round the clock, cross any river and spare no effort—all to meet someone’s need. We wrap our high quality products in high quality service.

Creating access to HIV/AIDS medications and physicians

Teamwork
Together, we can run faster, reach higher and achieve more than any one of us can alone. We relish opportunities to collaborate because it’s invigorating, enlightening and powerful. When we join forces and plow through boundaries, we move mountains.

Meet our leadership team

Mylan at a Glance

1961: Year founded in White Sulphur Springs, W.Va., U.S.
~7 billion: People we work to provide with access to high quality medicine
~140: Countries and territories in which our products are sold
~1,300: Separate products currently being marketed
54+ billion: Dose capacity
1 of 2: Global generics companies with true vertical integration
20,000+: Workforce

Fact Sheet